Perfluorooctyl Bromide Polymeric Capsules as Dual Contrast Agents for Ultrasonography and Magnetic Resonance Imaging
Authors:
- Nicolas TsapisNTNicolas Tsapis
- Nicolas TaulierNTNicolas Taulier
- Olivier LucidarmeOLOlivier Lucidarme
- Bich Thuy DoanBDBich Thuy Doan
- Jean Claude BeloeilJBJean Claude Beloeil
- Brigitte GilletBGBrigitte Gillet
- 6 October 2008
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 18 (19) , 2963-2971
Abstract
Polymeric capsules with a thick shell made of biodegradable and biocompatible polymer and a liquid core of perfluorooctyl bromide (PFOB) were evaluated for stability as well as for ultrasound and magnetic resonance imaging (MRI) contrast enhancement. The method of preparation allows the mean capsule diameter to be regulated between 70 nm and 25 µm and the capsule thickness‐to‐radius ratio from 0.25 to 0.54. Capsule diameter remains stable at 37 °C in phosphate buffer for at least 4 and 6 h for nanocapsules and microcapsules, respectively. The in vitro ultrasound signal‐to‐noise ratio (SNR) was measured from 40 to 60 MHz for 6 µm and 150 nm capsules: the SNR increases with capsule concentration up to 20–25 mg mL−1, and then reaches a plateau that depends on capsule diameter (13.5 ± 1.5 dB for 6 µm and 6 ± 2 dB for the 150 nm capsules). The ultrasound SNR is stable for up to 20 min for microcapsules and for several hours for nanocapsules. For nanocapsules, the thinner the shell, the larger the SNR and the more compressible the capsules. Nanocapsule suspensions imaged in vitro with a commercial ultrasound imaging system (normal and tissue harmonic imaging modes, 7–14 MHz probe) were detected down to concentrations of 12.5 mg mL−1. Injections of nanocapsules (200 µg ml−1) in mice in vivo reveal that the initial bolus passage presents significant ultrasound enhancement of the blood pool during hepatic imaging (7–14 MHz probe, tissue harmonic imaging mode). 19F‐MRI images were obtained in vitro at 9.4T using spin‐echo and gradient echo sequences and allow detecting nanocapsules in suspension (50 mg mL−1). In conclusion, these results show initial feasibility for development of these capsules toward a dual‐modality contrast agent.Keywords
This publication has 39 references indexed in Scilit:
- A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): Formulation and process optimizationInternational Journal of Pharmaceutics, 2006
- MRI of perfluorocarbon emulsion kinetics in rodent mammary tumoursPhysics in Medicine & Biology, 2005
- Preparation and evaluation of poly(L‐lactide‐co‐glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiographyJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2005
- Ultrasound degradation of novel polymer contrast agentsJournal of Biomedical Materials Research Part A, 2003
- High field human imagingJournal of Magnetic Resonance Imaging, 2003
- Development of a novel method for synthesis of a polymeric ultrasound contrast agentJournal of Biomedical Materials Research Part A, 2003
- Shell waves and acoustic scattering from ultrasound contrast agentsIEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2001
- Broad-band ultrasonic measurement techniques for liquidsMeasurement Science and Technology, 1996
- Biodegradable Long-Circulating Polymeric NanospheresScience, 1994
- In vivo19f spin relaxation in index finger bonesMagnetic Resonance in Medicine, 1990